PubMed Health⌕ Search

Biomedical subjects

T Hanabayashi

Publications and source records attributed to T Hanabayashi.

7 recordsLinked to original sources
PubMed1992

Neoadjuvant intraarterial infusion chemotherapy with a combination of mitomycin-C, vincristine, and cisplatin for locally advanced cervical cancer: a preliminary report.

Combination chemotherapy including cisplatin was administered intraarterially from the internal iliac artery as neoadjuvant chemotherapy to six patients with locally advanced uterine cervical cancer (stage higher than IIIB of FIGO). The drugs and doses were mitomycin-C 10 mg/m2, vincristine 1 mg/m2, and cisplatin 50 mg/m2. Two or three courses were repeated at intervals of 3 weeks. In three patients, dose reductions were undertaken for decreased renal function and thrombocytopenia. Partial response was, however, observed in all patients (response rate 100%), and five of six patients were able to undergo a radical hysterectomy. The major toxic effects were leukocytopenia, nausea, and vomiting. Our preliminary experience suggests that pelvic intraarterial infusion of combination chemotherapy is effective against primary and advanced uterine cervical cancer, and this preoperative treatment can lead to easier radical hysterectomy. However, further studies are warranted.

Aged↗
PubMed1992

Effects of sex steroids on cell differentiation and interleukin-1 beta production in the human promyelocytic leukemia cell line HL-60.

The effects of 17 beta-estradiol (E2), progesterone (P) and testosterone (Te) on cell differentiation in the HL-60 promyelocytic leukemia cells after treatment with 1 alpha, 25-dihydroxyvitamin D3 [1,25-(OH)2D3] and those on interleukin-1 beta (IL-1 beta) production by HL-60 cells in response to lipopolysaccharide (LPS) were investigated. Neither E2 (10(-10) to 10(-7) M), P (10(-9) to 10(-6) M) nor Te (10(-10) to 10(-7) M) affected monocytic differentiation as assessed by reactivity with OKM14 monoclonal antibody and alpha-naphthyl acetate esterase activity. Pretreatment of HL-60 cells with 1,25-(OH)2D3 enhanced their ability to produce IL-1 beta in response to subsequent exposure to LPS, although 1,25-(OH)2D3 by itself did not induce IL-1 beta production by HL-60 cells. This priming effect of 1,25-(OH)2D3 was augmented by the addition of E2 and Te at physiologic concentrations, but not by that of P. E2, P and Te at physiologic concentrations enhanced IL-1 beta production by HL-60 cells that were pretreated with 1,25(OH)2D3 and stimulated by LPS. The increasing rate of IL-1 beta production by the addition of E2 and Te was higher when added with LPS than when added with 1,25-(OH)2D3. These findings suggest that enhancing effects of sex steroids in IL-1 beta production by monocyte/macrophage lineage cells.

Analysis of Variance↗
PubMed1991

Effects of sex steroids on immunoglobulin M production by Epstein-Barr virus-transformed B-cell line SKW6-CL4.

The effects of estradiol (E2), progesterone (P), and testosterone (T) on the production of immunoglobulin (Ig) M by Epstein-Barr virus-transformed B-cell line, SKW6-CL4, were investigated. Interleukin 6 (IL-6) induced IgM production by SKW6-CL4 cells in a dose-dependent manner without any significant increase in thymidine incorporation. E2 at concentrations ranging from 10(-10) to 10(-9) M enhanced IL-6-induced IgM production by SKW6-CL4 cells, whereas E2 at a high concentration of 10(-7) M inhibited both the IgM production and the growth of SKW6-CL4 cells. Time-course studies revealed that E2 acts in the early phase of differentiation of SKW6-CL4 cells in response to IL-6. On the other hand, P and T at physiological and superphysiological levels did not influence either the IgM production or the proliferation of SKW6-CL4 cells. These findings suggest a direct immunoregulatory effect of E2 on human B lineage cells and support the concept that E2 may have a role in the pathogenesis of some autoimmune diseases.

B-Lymphocytes↗
PubMed1991

Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines.

The co-operative effects of recombinant human tumor necrosis factor (rH-TNF) and CPT-11, a new derivative of camptothecin, against the proliferation of human gynecologic tumor cell lines were examined in vitro. The ishikawa cells were responsive to rH-TNF, the HHUA cells exhibited a minimal degree of responsiveness to rH-TNF, and the HeLa S3 and Caov-3 cells were unresponsive to rH-TNF. The HHUA, Ishikawa and Caov-3 cells were responsive to CPT-11, and the HeLa S3 cells were relatively sensitive to CPT-11 cytotoxicity. In all four cell lines, rH-TNF at clinically achievable concentrations exhibited synergy with CPT-11. The combination therapy of rH-TNF and CPT-11 will be a new approach against gynecologic cancers.

Antineoplastic Agents, Phytogenic↗
PubMed1990

Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer.

The interferon-gamma (IFN-gamma) productivity of peripheral blood mononuclear cells (PBMCs) was examined in 30 patients with uterine cervical cancer. The patients under 50 years of age had decreased IFN-gamma production compared with the age-matched controls. The IFN-gamma productivity in the patients over 50 years of age was decreased as well as in the age-matched controls. The proportion of monocytes in PBMCs did not correlate with the IFN-gamma productivity. The prostaglandin E2 (PGE2) productivity of PBMCs increased with the progress of cancer. PGE2 inhibited the IFN-gamma production by PBMCs, and the sensitivity of PBMCs to PGE2 was increased in the patients and controls over 60 years of age. The addition of indomethacin resulted in an increase in IFN-gamma production by PBMCs. These results suggest that the increased production of PGE2 and/or increased sensitivity to PGE2 are responsible for the decreased IFN-gamma production in patients with cervical cancer.

Adult↗
PubMed1986

[Pharmacokinetic and clinical studies of cefotiam in the perinatal period].

Patients, who had undergone cesarean sections, and those who had experienced premature rupture of membranes, received cefotiam (CTM) and the clinical efficacy and the safety for mothers and fetuses were investigated. At the same time, pharmacokinetic analysis was done to study the maternal fetal transfer. Following results were observed. In cases of premature rupture of membranes, the maternal-fetal transfer ratio after intravenous administrations of CTM was 50.3% at a dosage of 1 g. Maternal and fetal serum concentrations of CTM were maintained higher levels than the MIC80 (0.78 micrograms/ml) against major pathogens excluding anaerobic of gynecologic-obstetric infections and were maintained up to 5.87 hours and 6.15 hours in mothers and fetuses, respectively. The CTM was administered once every 12 hours at a dosage of 1 g to 38 cases up to the 3rd or 4th day of puerperium after the rupture of membranes. Also, the CTM was administered up to times of delivery to another 20 cases, in one of which the fetus developed pneumonia. The maternal-fetal prophylactic effect was recognized in 98.3% (57/58) of cases. Forty-three cesarean section cases received CTM at a dosage level of 1 g by one-hour intravenous drip infusion in the following manner: after surgery to the 4th day, twice a day; from the 5th to the 7th day, once a day. Postoperative prophylactic effect against infection was achieved in all the cases. In 1 case, a slight transient elevation in the maternal GOT was observed. Neonatal jaundice with total bilirubin levels higher than 15.0 mg/dl was observed in 19 neonates (32.8%) in the group in which premature rupture of the membranes had occurred. However, the cause/effect relationship between CTM and the total bilirubin levels is unclear. The maternal-fetal transition of CTM was excellent, and the safety toward the fetus and neonate was high. When an antimicrobial activity and pharmacokinetics are considered, CTM will be a useful drug in the treatment of perinatal infections.

Amniotic Fluid↗